NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated...
42 insider purchases on record · latest filing 2026-08-20.
Insiders have also filed 20 sale transactions at NTHI.